2. Search Result
Search Result
Results for "

epoxygenases

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

2

Natural
Products

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114759
    MS-PPOH

    		Cytochrome P450 Neurological Disease Metabolic Disease Cancer
    MS-PPOH is a potent and selective cytochrome P450 (CYP) epoxygenase inhibitor . MS-PPOH inhibits CYP2C8 and CYP2C9 with IC50s of 15 and 11 μM, respectively . MS-PPOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MS-PPOH
  • HY-130419
    (±)13(14)-EpDPA

    13,14-EpDPE

    		 Others Cardiovascular Disease Neurological Disease
    (±)13(14)-EpDPA (13,14-EpDPE) is the product of the reaction of cytochrome P-450 epoxygenase with Docosahexaenoic Acid (DHA).(±)13(14)-EpDPA has antihyperalgesic and vasorelaxative activities .
    (±)13(14)-EpDPA
  • HY-N4237
    Saikogenin D

    		Prostaglandin Receptor Potassium Channel Inflammation/Immunology
    Saikogenin D is isolated from?Bupleurum chinense, has anti-inflammatory effects. Saikogenin D activates epoxygenases that converts arachidonic acid to epoxyeicosanoids and dihydroxyeicosatrienoic acids, and the metabolites secondarily inhibit prostaglandin E2 (PGE2) production. Saikogenin D results in an elevation of [Ca 2+]i due to Ca 2+ release from intracellular stores .
    Saikogenin D
  • HY-113040A
    (17R,18S)-Epoxyeicosatetraenoic acid

    17(R),18(S)-EETeTr

    		 Calcium Channel Cardiovascular Disease
    (17R,18S)-Epoxyeicosatetraenoic acid (17(R),18(S)-EETeTr) is a cytochrome P450 epoxygenase metabolite of eicosapentaenoic acid (HY-B0660). (17R,18S)-Epoxyeicosatetraenoic acid shows exerts negative chronotropic effects and protects neonatal rat cardiomyocytes against Ca 2+ overload. (17R,18S)-Epoxyeicosatetraenoic acid has the potential for the research of antiarrhythmic agent .
    (17R,18S)-Epoxyeicosatetraenoic acid
  • HY-126041A
    (±)10(11)-EpDPA

    (±)10,11-EDP; (±)10,11-EpDPE; (±)10,11-Epoxy docosapentaenoic acid

    		 Epoxide Hydrolase Metabolic Disease
    (±)10(11)-EpDPA, a docosahexaenoic acid epoxygenase metabolite, acts as a substrate for soluble epoxide hydrolase (sEH) with a Km value of 5.1 µM for human sEH .
    (±)10(11)-EpDPA
  • HY-130309
    (±)8(9)-EpETE

    (±)8,9-EEQ; (±)8,9-epoxy Eicosatetraenoic acid

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Eicosapentaenoic acid (EPA) is converted to epoxyeicosatetraenoic acids (EpETEs) by several cytochrome P450 isoforms. The major product of this epoxygenase pathway, (±)17(18)-EpETE, relaxes vascular and airway smooth muscle by activating large conductance Ca 2+-activated K + (BKCa) channels by directly interacting with BKα channel subunits. (±)8(9)-EpETE is an epoxygenase pathway product produced from EPA by CYP450 both in vitro and in vivo.
    (±)8(9)-EpETE
  • HY-120178
    (±)7(8)-DiHDPA

    		Others Cardiovascular Disease
    (±)7(8)-DiHDPA is a epoxygenase metabolite of docosahexaenoic acid (HY-B2167). (±)7(8)-DiHDPA inhibits platelet aggregation at concentrations below those affecting thromboxane synthesis .
    (±)7(8)-DiHDPA
  • HY-120442
    (±)16(17)-DiHDPA

    		Others Cardiovascular Disease
    (±)16(17)-DiHDPA is a epoxygenase metabolite of docosahexaenoic acid (HY-B2167). (±)16(17)-DiHDPA inhibits platelet aggregation at concentrations below those affecting thromboxane synthesis .
    (±)16(17)-DiHDPA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: